CN112098649A - 一种检测肝癌患者血清生物标志物的信号控释纳米材料及其制备方法 - Google Patents
一种检测肝癌患者血清生物标志物的信号控释纳米材料及其制备方法 Download PDFInfo
- Publication number
- CN112098649A CN112098649A CN202010821541.6A CN202010821541A CN112098649A CN 112098649 A CN112098649 A CN 112098649A CN 202010821541 A CN202010821541 A CN 202010821541A CN 112098649 A CN112098649 A CN 112098649A
- Authority
- CN
- China
- Prior art keywords
- nano
- signal controlled
- release
- afp
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002086 nanomaterial Substances 0.000 title claims abstract description 45
- 238000013270 controlled release Methods 0.000 title claims abstract description 42
- 210000002966 serum Anatomy 0.000 title claims abstract description 19
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 15
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000090 biomarker Substances 0.000 title abstract description 5
- 238000001514 detection method Methods 0.000 claims abstract description 39
- 229920001690 polydopamine Polymers 0.000 claims description 26
- 239000010931 gold Substances 0.000 claims description 20
- 229910052737 gold Inorganic materials 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 20
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 14
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 12
- 239000000439 tumor marker Substances 0.000 claims description 8
- 229960003638 dopamine Drugs 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Substances [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 239000002103 nanocoating Substances 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical group [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 2
- 229940043267 rhodamine b Drugs 0.000 claims description 2
- 239000002539 nanocarrier Substances 0.000 claims 3
- 238000007259 addition reaction Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 abstract description 52
- 238000000034 method Methods 0.000 abstract description 24
- 230000035945 sensitivity Effects 0.000 abstract description 15
- 206010028980 Neoplasm Diseases 0.000 abstract description 10
- 230000003321 amplification Effects 0.000 abstract description 8
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 8
- 102000004190 Enzymes Human genes 0.000 abstract description 7
- 108090000790 Enzymes Proteins 0.000 abstract description 7
- 238000013399 early diagnosis Methods 0.000 abstract description 6
- 102000003992 Peroxidases Human genes 0.000 abstract description 4
- 239000003550 marker Substances 0.000 abstract description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 abstract description 2
- 238000012544 monitoring process Methods 0.000 abstract description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 abstract 4
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 49
- 239000002088 nanocapsule Substances 0.000 description 8
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001917 fluorescence detection Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000036046 immunoreaction Effects 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006845 Michael addition reaction Methods 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000827785 Homo sapiens Alpha-fetoprotein Proteins 0.000 description 1
- 101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002998 adhesive polymer Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960001149 dopamine hydrochloride Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 102000046101 human AFP Human genes 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57476—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofetal proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Nanotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010821541.6A CN112098649B (zh) | 2020-08-15 | 2020-08-15 | 一种检测肝癌患者血清生物标志物的信号控释纳米材料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010821541.6A CN112098649B (zh) | 2020-08-15 | 2020-08-15 | 一种检测肝癌患者血清生物标志物的信号控释纳米材料及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112098649A true CN112098649A (zh) | 2020-12-18 |
CN112098649B CN112098649B (zh) | 2022-12-02 |
Family
ID=73752884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010821541.6A Expired - Fee Related CN112098649B (zh) | 2020-08-15 | 2020-08-15 | 一种检测肝癌患者血清生物标志物的信号控释纳米材料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112098649B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140336040A1 (en) * | 2012-01-05 | 2014-11-13 | Nanyang Technological University | Methods of preparing monodispersed polydopamine nano- or microspheres, and methods of preparing nano- or microstructures based on the polydopamine nano- or microspheres |
CN105738457A (zh) * | 2016-03-07 | 2016-07-06 | 济南大学 | 一种基于金属基标记同时检测两种肿瘤标志物的磁性电化学免疫传感器的制备方法及应用 |
CN106248951A (zh) * | 2016-07-11 | 2016-12-21 | 福州市传染病医院 | 一种检测galectin‑4的荧光酶联免疫分析方法 |
WO2019067656A1 (en) * | 2017-09-29 | 2019-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | POLYDOPAMIN ENCAPSULATED NANODIAMANTS AND RELATED METHODS |
-
2020
- 2020-08-15 CN CN202010821541.6A patent/CN112098649B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140336040A1 (en) * | 2012-01-05 | 2014-11-13 | Nanyang Technological University | Methods of preparing monodispersed polydopamine nano- or microspheres, and methods of preparing nano- or microstructures based on the polydopamine nano- or microspheres |
CN105738457A (zh) * | 2016-03-07 | 2016-07-06 | 济南大学 | 一种基于金属基标记同时检测两种肿瘤标志物的磁性电化学免疫传感器的制备方法及应用 |
CN106248951A (zh) * | 2016-07-11 | 2016-12-21 | 福州市传染病医院 | 一种检测galectin‑4的荧光酶联免疫分析方法 |
WO2019067656A1 (en) * | 2017-09-29 | 2019-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | POLYDOPAMIN ENCAPSULATED NANODIAMANTS AND RELATED METHODS |
Non-Patent Citations (2)
Title |
---|
XIAOYU LIANG等: "pH responsive amperometric immunoassay for carcinoma antigen 125 based on hollow polydopamine encapsulating methylene blue", 《SENSORS & ACTUATORS: B. CHEMICAL》 * |
王贝贝等: "聚多巴胺/金纳米空心球的原位制备及其在电化学免疫分析中的应用", 《湖北省第五届大学生化学(化工)学术创新成果报告会论文集》 * |
Also Published As
Publication number | Publication date |
---|---|
CN112098649B (zh) | 2022-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Syedmoradi et al. | Point-of-care cancer diagnostic devices: From academic research to clinical translation | |
Zhao et al. | based laser induced fluorescence immunodevice combining with CdTe embedded silica nanoparticles signal enhancement strategy | |
CN114235907B (zh) | 用于非小细胞肺癌cyfra21-1检测的电化学发光免疫传感器及检测方法 | |
CN111766289B (zh) | 一种基于富氧空位CeO2电致化学发光免疫传感器的制备方法 | |
CN109884029B (zh) | 银/石墨烯量子点纳米酶、sers检测试剂盒及应用 | |
WO2021180132A1 (zh) | 基于Fe2O3材料单层光电化学传感器的癌胚抗原检测方法 | |
CN110133252A (zh) | 用于检测癌胚抗原的试剂盒和检测方法及其应用 | |
Kavetskyy et al. | Magneto-immunoassay of cancer biomarkers: Recent progress and challenges in biomedical analysis | |
CN109613244B (zh) | 一种Ag@Pt-CuS标记的免疫传感器的制备方法及应用 | |
CN111693571A (zh) | 一种基于光寻址电位传感器检测gpc3的方法 | |
CN112834465B (zh) | SPR生物传感芯片、芯片修饰方法、SARS-CoV-2检测试剂盒和检测方法 | |
Zhong et al. | Dual-wavelength responsive photoelectrochemical aptasensor based on ionic liquid functionalized Zn-MOFs and noble metal nanoparticles for the simultaneous detection of multiple tumor markers | |
CN113155930A (zh) | 一种多重信号放大技术检测白血病干细胞肿瘤标志物cd123的电化学免疫传感方法 | |
Lu et al. | Detection of squamous cell carcinoma antigen in cervical cancer by surface-enhanced Raman scattering-based immunoassay | |
CN112098648B (zh) | 一种检测肝癌患者血清生物标志物的方法 | |
CN112098649B (zh) | 一种检测肝癌患者血清生物标志物的信号控释纳米材料及其制备方法 | |
CN112526135A (zh) | 一种检测前列腺特异性抗原的光电化学生物传感器的制备方法及应用 | |
CN108445213A (zh) | 一种高灵敏度荧光定量检测血清肿瘤标志物的纳米复合探针、组合物及荧光定量试剂盒 | |
CN109991298B (zh) | 一种Pt@MOF-GO标记的电化学传感器的制备方法及应用 | |
CN112305053A (zh) | 一种硫化铟纳米微球修饰的标记电化学免疫传感器及其电化学免疫分析方法 | |
CN114924074B (zh) | 一种用于检测乳腺癌her2的电化学免疫传感器及其检测方法 | |
Tang et al. | Multiplexed electrochemical immunoassay for two immunoglobulin proteins based on Cd and Cu nanocrystals | |
CN111766288B (zh) | 一种基于富氧空位NiCo2O4电致化学发光传感器的制备方法 | |
CN115656303A (zh) | 基于Fe-MOF模拟酶的无标记电化学免疫分析方法 | |
KR20230102652A (ko) | 결핵균 항원 또는 항체 검출용 산화아연 나노선 어레이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230602 Address after: No. 201, 2nd Floor, Comprehensive Building 1, E-commerce Industrial Park, National Xuchang Economic and Technological Development Zone, 100 meters southeast of the intersection of Ruixiang Road and Ziyang Road, Xuchang City, Henan Province, 461000 Patentee after: Xuchang Boao Runkang Medical Laboratory Co.,Ltd. Address before: 230000 floor 1, building 2, phase I, e-commerce Park, Jinggang Road, Shushan Economic Development Zone, Hefei City, Anhui Province Patentee before: Dragon totem Technology (Hefei) Co.,Ltd. Effective date of registration: 20230602 Address after: 230000 floor 1, building 2, phase I, e-commerce Park, Jinggang Road, Shushan Economic Development Zone, Hefei City, Anhui Province Patentee after: Dragon totem Technology (Hefei) Co.,Ltd. Address before: 266000 Songling Road, Laoshan District, Qingdao, Shandong Province, No. 99 Patentee before: QINGDAO University OF SCIENCE AND TECHNOLOGY |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20221202 |
|
CF01 | Termination of patent right due to non-payment of annual fee |